Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Kinner

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
European Journal of Neurology|October 21, 2020
Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathyMarkus Kinner, Christian Prehn, Ruth Schneider, et al.
CNS Neuroscience & Therapeutics|October 15, 2016
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple SclerosisMarkus Kinner, Robert Hoepner, Peter Klotz, et al.
Journal of Neurology|November 16, 2019
Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificityThomas Grüter, Anthonina Ott, Wolfgang Meyer, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
European Journal of Neurology|October 21, 2020
Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathyMarkus Kinner, Christian Prehn, Ruth Schneider, et al.
CNS Neuroscience & Therapeutics|October 15, 2016
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple SclerosisMarkus Kinner, Robert Hoepner, Peter Klotz, et al.
Journal of Neurology|November 16, 2019
Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificityThomas Grüter, Anthonina Ott, Wolfgang Meyer, et al.
Pageof 1